A novel nanotechnology-based therapy has shown promise in reversing symptoms of Alzheimer’s disease in mice, offering a potential breakthrough in the fight against the debilitating neurodegenerative condition, which affects an estimated 6.7 million Americans [1]. Researchers at the Institute of Bioengineering of Catalonia (IBEC) and West China Hospital of Sichuan University have focused on restoring function to the blood-brain barrier, a critical but often overlooked aspect of Alzheimer’s pathology, through the use of targeted nanoparticles. The findings, published in Signal Transduction and Targeted Therapy, represent a new avenue of research aiming to clear amyloid plaques and restore cognitive function.
Researchers have reversed symptoms of Alzheimer’s disease in mice using a novel nanotechnology-based therapy, offering a potential new avenue for treating the devastating neurological condition. Alzheimer’s disease affects millions worldwide, and finding effective treatments remains a critical public health priority.
Instead of targeting neurons or other brain cells directly, the research team focused on restoring the function of the blood-brain barrier, the vascular system that regulates the brain’s environment. This was achieved through the injection of bioactive nanoparticles.
The study, led by a team from the Institute of Bioengineering of Catalonia (IBEC) and West China Hospital of Sichuan University, demonstrated a reversal of Alzheimer’s symptoms after just three injections of these supramolecular drugs.
“Just one hour after the first injection, we observed a 50%-60% reduction in the amount of beta-amyloid accumulated within the brain, and after three doses, we found a recovery of cognitive abilities equivalent to a rejuvenation of 20-30 years in humans,” explained Lorena Ruiz Pérez, from the IBEC’s Molecular Bionics group.
The researchers emphasize that their work confirms the crucial role of vascular health in the development of diseases like dementia and Alzheimer’s.
Specifically, the team focused on the blood-brain barrier, which separates the brain from the bloodstream to protect it from external threats like pathogens and toxins.
In Alzheimer’s disease, the brain’s natural system for eliminating toxins, such as the beta-amyloid protein, malfunctions, leading to a buildup that disrupts normal neuron function.
“Normally, the LRP1 protein acts as a molecular guardian: it recognizes beta-amyloid, binds to it through ligands, and transports it across the blood-brain barrier into the bloodstream, where it can be cleared,” according to sources at IBEC.
However, this system is fragile. “If LRP1 binds to too much beta-amyloid too strongly, the transport becomes blocked and the protein degrades, leaving fewer LRP1 carriers available; and if it binds to too little, the signal is too weak to activate transport. In both cases, the result is the same: beta-amyloid accumulates within the brain.”
This led the researchers to develop supramolecular drugs that mimic LRP1 ligands to bind to beta-amyloid, cross the blood-brain barrier, and initiate its removal from the brain, while also restoring the balance of the vascular system to allow it to fulfill its natural role as a waste-clearing pathway.
In their experiment, the researchers used mouse models that are genetically programmed to produce higher amounts of beta-amyloid and develop significant cognitive impairment mimicking Alzheimer’s disease.
They administered three doses of the supramolecular drugs and then regularly monitored the progression of the disease with various experiments to analyze animal behavior and measure memory deterioration over several months.
In one experiment, a 12-month-old mouse (equivalent to a 60-year-old human) was treated with the nanoparticles, and its behavior was analyzed after six months – when the animal was 18 months old (comparable to a 90-year-old human). Researchers found the mouse’s behavior was comparable to that of a healthy mouse.
“The long-term effect comes from the restoration of the brain’s vascular system. We believe it works like a cascade: when toxic species like beta-amyloid accumulate, the disease progresses; but once the vascularization can function again, it begins to eliminate beta-amyloid and other harmful molecules, allowing the entire system to regain its balance,” explained Giuseppe Battaglia, Icrea research professor at IBEC and leader of the study.
He believes that “the most relevant aspect is that our nanoparticles act like a drug and appear to activate a feedback mechanism that returns this elimination pathway to normal levels.”
Both Battaglia and Ruiz Pérez believe this achievement, published in the journal Signal Transduction and Targeted Therapy, “is a promising step towards an effective treatment for Alzheimer’s disease.”
Experts in the field who were not involved in the research acknowledge that this is a novel study that focuses on a relatively unexplored target in Alzheimer’s research and appears to eliminate amyloid very quickly and markedly in animals.
However, they remain cautious about its clinical application for treating patients with Alzheimer’s disease because results in mice do not always translate to effectiveness in humans.
“As is always the case with animal studies, its potential application in humans will need to be evaluated based on the characteristics of the drug,” noted Alberto Lleó, a neurologist and director of the Memory Unit at Sant Pau Hospital in Barcelona.
